BioTime to host key opinion leader event on dry AMD on July 25
BioTime announced that it will host a Key Opinion Leader event on the topic of dry age-related macular degeneration in New York City on Tuesday, July 25. The meeting will feature a presentation by key opinion leader David S. Boyer, MD, Retina-Vitreous Associates, who will discuss the clinical perspective and cell therapy treatment options for patients with dry age-related macular degeneration. BioTime's management team will also provide an overview of the Company's ongoing clinical development work with OpRegen, being studied for patients with dry AMD, including recently presented new clinical trial data from this year's Annual Meeting of the Association for Research in Vision and Ophthalmology. OpRegen is now in a Phase I/IIa dose finding study to evaluate its safety and efficacy in patients who have an advanced stage of the disease, and has received fast track designation by the FDA.